Current and investigational therapies used to alter the course of disease in multiple sclerosis

Southern Medical Journal

Volumn 90, Issue 4, 1997, Pages 367-375

  Miller, Aaron ^a,b,c  

^a Maimonides Medical Center ^*

^b MAIMONIDES MEDICAL CENTER   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIAMINOPYRIDINE; 4 AMINOPYRIDINE; ALEMTUZUMAB; AZATHIOPRINE; BETA1A INTERFERON; CHIMERIC ANTIBODY; CLADRIBINE; CORTICOSTEROID; CORTICOTROPIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLATIRAMER; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERFERON; INTERFERON BETA SERINE; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; POTASSIUM CHANNEL BLOCKING AGENT; PREDNISOLONE; PREDNISONE; RECEPTOR PROTEIN; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT BETA INTERFERON; ROQUINIMEX; T LYMPHOCYTE RECEPTOR;

ARTICLE; AUTOIMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DISABILITY; DOUBLE BLIND PROCEDURE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE IRRADIATION; META ANALYSIS; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHYSIOTHERAPY; PLASMAPHERESIS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030944188     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007611-199704000-00001     Document Type: Article

References (56)

1. Bastianello S, Pozzilli C, Bernardi S, et al: Serial study of gadolinium-DPTA MRI enhancement in multiple sclerosis. Neurology 1990; 40:591-595
2. Antel JP, Arnason BGW: Demyelinating diseases. Harrison's Principles of Internal Medicine. Wilson JD, Braunwald E, Isselbacher KJ, et al (eds). New York, McGraw-Hill, 12th Ed, 1991, pp 2038-2045
3. Whitaker JN: Rationale for immunotherapy in multiple sclerosis. Ann Neurol 1994; 36(suppl):S103-S107
4. Lublin FD, Reingold SC: Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46:907-911
5. Weinshenker BG, Bass B, Rice GPA, et al: The natural history of multiple sclerosis: a geographically based study: I. Clinical course and disability. Brain 1989; 112:133-146
6. Connelly JF: Interferon beta for multiple sclerosis. Ann Pharmacother 1994; 28:610-616
7. Weiner HL, Hafler DA: Immunotherapy of multiple sclerosis. Ann Neurol 1988; 23:211-222
8. Cutler RW: Demyelinating disease. Scientific American Medicine: Neurology. Rubenstein E, Federman DD (eds). New York, Scientific American, 1987, pp 1-5
9. Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33:1444-1452
10. Miller DH: Magnetic resonance in monitoring the treatment of multiple sclerosis. Ann. Neurol 1994; 36(suppl):S91-S94
11. Husted C: Contributions of neuroimaging to diagnosis and monitoring of multiple sclerosis. Curr Opin Neurol 1994; 7:234-241
12. Noseworthy JH: Review: therapeutics of multiple sclerosis. Clin Neuropharmacol 1991; 14:49-61
13. Matthews WB: Treatment. McAlpine's Multiple Sclerosis. Matthews WB (ed). New York, Churchill-Livingstone, 2nd Ed, 1991, pp 251-298
14. Physician's Desk Reference. Montvale, NJ, Medical Economics Data Production Co, 50th Ed, 1996, pp 658-663
15. Arnason BGW, Reder AT: Interferons and multiple sclerosis. Clin Neuropharmacol 1994; 17:495-547
16. Weinstock-Guttman B, Ransohoff RM, Kinkel RP, et al: The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol 1995; 37:7-15
17. Panitch HS: Interferons in multiple sclerosis: a review of the evidence. Drugs 1992; 44:946-962
18. The IFNB Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43:655-661
19. The IFNB Multiple Sclerosis Study Group, the University of British Columbia MS/MRI Analysis Group: Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized, controlled trial. Neurology 1995; 45:1277-1285
20. Goodkin DE: Role of steroids and immunosuppression and effects of interferon beta-lb in multiple sclerosis. West J Med 1994; 161:292-298
21. Jacobs LD, Cookfair DL, Rudick RA, et al: Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39:285-294
22. Investigators report on new MS drug (Special Report). MS Quarterly Report 1994; 13:1-2
23. Simon JH, Jacobs L, Cookfair D, et al: The natural history of MS based on an annual MR snapshot: results from the MSCRG study of intramuscular recombinant interferon beta-1a (Abstract). Neurology 1995; 45(suppl 4):A418
24. Durelli L, Bongioanni MR, Cavallo R, et al: Chronic systemic high-dose recombinant interferon alpha-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 1994; 44:406-413
25. Miller H, Newell DJ, Ridley A: Multiple sclerosis: trials of maintenance treatment with prednisolone and soluble aspirin. Lancet 1961; 1:127-129
26. Millar JHD, Vas CJ, Noronha MJ, et al: Long-term treatment of multiple sclerosis with corticotrophin. Lancet 1967; 2:429-431
27. Compston DAS, Milligan NM, Hughes PJ, et al: A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: II. Laboratory results. J Neurol Neurosurg Psychiatry 1987; 50:517-522
28. Beck RW, Cleary PA, Trobe JD, et al: The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993; 329:1764-1769
29. Kupersmith MJ, Kaufman D, Paty DW, et al: Megadose corticosteroids in multiple sclerosis (Editorial). Neurology 1994; 44:1-4
30. Frequin STFM, Lamers KJB, Barkhof F, et al: Follow-up study of MS patients treated with high-dose intravenous methylprednisolone. Acta Neurol Scand 1994; 90:105-110
31. Yudkin PL, Ellison GW, Ghezzi A, et al: Overview of azathioprine treatment in multiple sclerosis. Lancet 1991; 338:1051-1055
32. Goodkin DE, Bailly RC, Teetzen ML, et al: The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology 1991; 41:20-25
33. The Canadian Cooperative Multiple Sclerosis Study Group: The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991; 337:441-446
34. Noseworthy JH, Ebers GC, Roberts R: Cyclophosphamide and MS (Letter). Neurology 1994; 44:579-581
35. Smith DR, Balochov KE, Hafler DA, et al: Pulse intravenous cyclophosphamide therapy induces a shift from a Th1-to a Th2-type cytokine profile in multiple sclerosis patients (Abstract). Neurology 1995; 45(suppl 4):A213
36. The Multiple Sclerosis Study Group: Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol 1990; 27:591-605
37. Kappos L, Patzold U, Dommasch D, et al: Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis: results of the German multicenter study. Ann Neurol 1988; 23:56-63
38. Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al: Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995; 37:30-40
39. Karussis D, Meiner Z, Lehmann D, et al: Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: results of a double-blind placebo-controlled study with monthly MRI evaluation (Abstract). Neurology 1995; 45(suppl 4):A417
40. Johnson KP: Experimental therapy of relapsing-remitting multiple sclerosis with copolymer-1. Ann Neurol 1994; 36(suppl):S115-S117
41. Bornstein MB, Miller A, Slagle S, et al: A pilot trial of COP 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987; 317:408-414
42. Johnson KP, Brooks BR, Cohen JA, et al: Copolymer 1 reduces the relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial.Neurology 1995; 45:1268-1276
43. Compston A: Future prospects for the management of multiple sclerosis. Ann Neurol 1994; 36(suppl):S146-S150
44. Hale G, Xia M-Q, Tighe HP, et al: The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990; 35:118-127
45. Vandenbark AA, Chou YK, Whithan R, et al: Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nature Med 1996; 2:1109-1115
46. Sipe JC, Romine JS, Koziol JA, et al: Cladribine in the treatment of chronic progressive multiple sclerosis. Lancet 1994; 344:9-13
47. Sipe JC, Romine J, Koziol J, et al: Cladribine treatment of chronic progressive (C/P) MS: a double-blind, crossover study with 2+ years' observation (Abstract). Neurology 1995; 45(suppl 4):A418
48. Cook SD, Devereux C, Troiano R, et al: Effect of total lymphoid irradiation in chronic progressive multiple sclerosis. Lancet 1986; 1:1405-1409
49. Cook SD, Bansil S, Boos J, et al: Total lymphoid irradiation (TLI) and low-dose prednisone (LDP) in progressive multiple sclerosis (PMS) (Abstract). Neurology 1995; 45(suppl 4):A417
50. Khatri BO, McQuillen MP, Harrington GJ, et al: Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs. Neurology 1985; 35:312-319
51. Dijkstra CD, Polman CH, Berkenbosch F: Multiple sclerosis: some possible therapeutic opportunities. Trends Pharmacol Sci 1993; 14:124-129
52. Groves AK, Barnett SC, Franklin RJM, et al: Repair of demyelinated lesions by transplantation of purified O-2A progenitor cells (Letter). Nature 1993; 362:453-455
53. Grinspan JB, Stern J, Franceschini B, et al: Protein growth factors as potential therapies for central nervous system demyelinative disorders. Ann Neurol 1994; 36(suppl):S140-S142
54. Bever CT Jr: The current status of studies of aminopyridines in patients with multiple sclerosis. Ann Neurol 1994; 36(suppl):S118-S121
55. Waxman SG: Membranes, myelin, and the pathophysiology of multiple sclerosis. N Engl J Med 1982; 306:1529-1532
56. Polman CH, Bertelsmann FW, van Loenen AC, et al: 4-Aminopyridine in the treatment of patients with multiple sclerosis. Arch Neurol 1994; 51:292-296